DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06154486

Completed

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Healthy volunteers, Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Prevalence of full stomach after fasting for at least 8 hours

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06154486
Org study ID69273023.7.0000.0071

Timeline

Milestones

Study start2023-06-19actual
Primary completion2023-06-19actual
Study completion2023-08-22actual
Study first posted2023-12-04actual
Last update posted2023-12-04actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteersPerioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Sampling methodProbability sample

Study population text

30 volunteers will be included in the study, of which 15 must be currently using semaglutide and 15 must not be using the medication. The gastric ultrasonography will be performed at Hospital Israelita Albert Einstein, in the radiologist medicine sector, by an anesthesiologist with experience in gastric ultrasonography. The images will be registered in the picture archiving and communication system and reviewed by a radiologist.

Inclusion criteria

•• Adult individuals (aged 18 or over).
–Individuals currently using semaglutide.
–Individuals fasting for at least 8 hours for solids and 2 hours for clear liquids without residue.

Exclusion criteria

•Pregnant women and postpartum women.
–Individuals with technical limitations to perform gastric content assessment using ultrasonography
–Presence of risk factors for gastroparesis.
–Use of drugs from the prokinetic class, which accelerate gastric emptying, such as bromopride, metoclopramide and domperidone.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Safety / tolerability / PK
1
Other clinical outcomes
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Incidence of symptoms associated with medication use

Time frame:1 day

descriptive, event

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

prevalence of full stomach after fasting for at least 8 hours

Time frame:1 day

categorical status, event

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

demographic distribution

Time frame:1 day

descriptive

Secondary/protocol endpoint/low confidence

medication information

Time frame:1 day

descriptive

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.